UK-369003

CAS No. 334827-98-4

UK-369003 ( Gisadenafil besylate )

Catalog No. M14135 CAS No. 334827-98-4

UK-369003 (Gisadenafil besylate) is a novel, potent, selective, orally bioavailable PDE5 inhibitor with IC50 of 1.23 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 224 Get Quote
50MG 799 Get Quote
100MG 1206 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    UK-369003
  • Note
    Research use only, not for human use.
  • Brief Description
    UK-369003 (Gisadenafil besylate) is a novel, potent, selective, orally bioavailable PDE5 inhibitor with IC50 of 1.23 nM.
  • Description
    UK-369003 (Gisadenafil besylate) is a novel, potent, selective, orally bioavailable PDE5 inhibitor with IC50 of 1.23 nM, displays 117-fold selectivity over PDE6; demonstrates efficacy in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).COPD Phase 2 Discontinued
  • Synonyms
    Gisadenafil besylate
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE
  • Research Area
    Inflammation/Immunology
  • Indication
    COPD

Chemical Information

  • CAS Number
    334827-98-4
  • Formula Weight
    677.79
  • Molecular Formula
    C23H33N7O5S.C6H6O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCC1=C2C(=NN1CCOC)C(=O)NC(=N2)C3=C(N=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC.C1=CC=C(C=C1)S(=O)(=O)O
  • Chemical Name
    5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one benzenesulfonate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Rawson DJ, et al. Bioorg Med Chem. 2012 Jan 1;20(1):498-509.
2. Martínez-Salamanca JI, et al. Eur Urol. 2011 Sep;60(3):527-35.
3. Watson KJ, et al. Drug Metab Dispos. 2011 Jul;39(7):1203-13.
molnova catalog
related products
  • SEP-0372814

    SEP-0372814 is a potent inhibitor of PDE10.

  • Ensifentrine

    Ensifentrine is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.

  • Anagrelide

    Anagrelide is a Platelet-reducing Agent. The mechanism of action of anagrelide is as a Phosphodiesterase 3 Inhibitor.